Suggested Remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for previously treated oesophageal or gastro-oesophageal junction cancer.
Following on from information provided to NICE by the company in April 2019, the appraisal of Pembrolizumab for treated oesophageal or gastro-oesophageal junction cancer [ID1357] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1357
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Merck Sharp & Dohme (pembrolizumab)
- Others
- Department for Health and Social Care
- NHS England
- Welsh Government
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Accord Healthcare (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
- Actavis UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
- Celgene (paclitaxel) (not signed confidentiality agreement)
- Hospira UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
- Medac GmbH (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement)
- Pfizer Ltd (irinotecan) (not signed confidentiality agreement)
- Sanofi (docetaxel) (not signed confidentiality agreement)
- Seacross Pharmaceuticals (docetaxel, irinotecan) (not signed confidentiality agreement)
- Shire Pharmaceuticals (irinotecan) (not signed confidentiality agreement)
- General commentators
- All Wales Therapeutic and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
- National Cancer Research Institute
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019, the appraisal of Pembrolizumab for treated oesophageal or gastro-oesophageal junction cancer [ID1357] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2019 | The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 11 April 2019 | Suspended. Appraisal suspended |
| 07 March 2019 | Invitation to participate |
| 04 April 2018 - 02 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 01 March 2017 | In progress. DH Referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual